TITLE:
Synthesis and Radiation Dosimetry of [68Ga]-Ga-Lys1, Lys3-DOTA-Bombesin (1,14) Antagonist for PET-Imaging, as a Potential Theragnostic Tracer in Oncology
AUTHORS:
Juan C. Manrique-Arias, Quetzali Pitalua-Cortes, Roberto Pedrero-Piedras, Géiser Rodríguez-Mena, Tessy López, Cristian Cabezas-Ortiz, Osvaldo García-Pérez
KEYWORDS:
Radiation Dosimetry, Biodistribution, PET Imaging, Radiopharmaceutical, Lys1, Lys3-DOTA-BBN (1, 14), Bombesin Analogs
JOURNAL NAME:
Journal of Encapsulation and Adsorption Sciences,
Vol.10 No.2,
June
22,
2020
ABSTRACT: This
Bombesin (BBN), a tetradecapeptide analog of human gastrin-releasing peptide (GRP) with a high binding affinity for GRP
receptors (GRPR), is over- expressed
in early stages of androgen-dependent prostate carcinomas, but not in advanced stages.
Therefore, there is a need to develop effective tracers for the accurate and
specific detection of this disease. The objective of this study was to evaluate
Lys1, Lys3-DOTA-BBN (1,14) analog with the radiolabeled
positron emitter [68Ga]-Ga-BBN for receptor imaging with PET, and to
determine its biodistribution and radiation dosimetry using whole-body (WB) PET
scans in healthy volunteers. The highest uptake was in the pancreas, followed
by urinary bladder. The critical organ was pancreas with a mean absorbed dose
of 206 ± 0.7, 210 ± 0.7, 120 ± 0.9, 390.23 ± 0.6 μGy/MBq and the effective
doses were estimated as 73.2 ± 0.6, 49.8 ± 0.3 μGy/MBq (women and men,
respectively).